We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
Trial record 2 of 263745 for:    ALL

Effect of Vitamin D on Everolimus Trough Concentrations Among Heart Transplanted Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03403647
Recruitment Status : Enrolling by invitation
First Posted : January 18, 2018
Last Update Posted : January 18, 2018
Information provided by (Responsible Party):

Study Description
Brief Summary:
Vitamin D is part of the regular treatment regimen among patients after heart transplantation. Due to potential drug-drug interaction between vitamin D and everolmus, these patients are in increased risk for increased everolimus metabolism, potentially leading to under- immunosupression.

Condition or disease Intervention/treatment
Vitamin D Deficiency Dietary Supplement: Vitamin D

Detailed Description:
post heart transplantation patients treated with everolimus will be screened for vitamin D levels. Patients defined as deficient will be treated with vitamin D with close and intensive monitoring everolimus levels, adjusting oral daily dose to maintain therapeutic levels.

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Effect of Normalizing Vitamin D Concentrations on Everlomius Trough Concentrations
Anticipated Study Start Date : January 2018
Estimated Primary Completion Date : April 2018
Estimated Study Completion Date : June 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Vitamin D
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Vitamin D deficient
Vitamin D supplementation and close everolimus trough levels monitoring with oral dose adjustments
Dietary Supplement: Vitamin D
Oral daily vitamin D
No Intervention: No vitamin D deficiency
Regular and routine monitoring

Outcome Measures

Primary Outcome Measures :
  1. Oral daily everolimus dose change [ Time Frame: 8 weeks ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Heart transplanted patients treated with everolimus

Exclusion Criteria:

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03403647

Sheba Medical Center
Ramat Gan, Israel
Sponsors and Collaborators
Sheba Medical Center
More Information

Responsible Party: Dr.Itai Gueta, Physician in the institute for clinical pharmacology, Sheba Medical Center
ClinicalTrials.gov Identifier: NCT03403647     History of Changes
Other Study ID Numbers: Vitamin D and Everolimus
First Posted: January 18, 2018    Key Record Dates
Last Update Posted: January 18, 2018
Last Verified: January 2018

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Vitamin D Deficiency
Deficiency Diseases
Nutrition Disorders
Vitamin D
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors